Last reviewed 2026-05-23 · How we verify

Gestronol Caproate (GESTONORONE CAPROATE)

Phase 2 active Small molecule ✓ Verified May 2026

Gestronol Caproate (generic name: GESTONORONE CAPROATE) is a gestonorone caproate drug. It is currently in Phase 2 development.

Gestonorone caproate is a prodrug that is converted into gestonorone, a potent androgen receptor agonist.

Gestronol Caproate is a small molecule medication. It is also known by various synonyms, including Gestonorone Caproate, Caproate de Gestonorone, and Depostat.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GESTONORONE CAPROATE
Drug class	gestonorone caproate
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

This means that gestonorone caproate works by being converted into gestonorone in the body, which then binds to androgen receptors, mimicking the effects of male hormones like testosterone. This can help to treat conditions related to low androgen levels, such as low libido or fatigue. However, the exact effects of gestonorone caproate on the body are not well understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Gestronol Caproate CI brief — competitive landscape report
Gestronol Caproate updates RSS · CI watch RSS

Frequently asked questions about Gestronol Caproate

What is Gestronol Caproate?

Gestronol Caproate (GESTONORONE CAPROATE) is a gestonorone caproate drug.

How does Gestronol Caproate work?

Gestonorone caproate is a prodrug that is converted into gestonorone, a potent androgen receptor agonist.

What is the generic name of Gestronol Caproate?

GESTONORONE CAPROATE is the generic (nonproprietary) name of Gestronol Caproate.

What drug class is Gestronol Caproate in?

Gestronol Caproate belongs to the gestonorone caproate class. See all gestonorone caproate drugs at /class/gestonorone-caproate.

What development phase is Gestronol Caproate in?

Gestronol Caproate is in Phase 2.

Drug class: All gestonorone caproate drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing